Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.25)
# 450
Out of 5,103 analysts
502
Total ratings
48.69%
Success rate
17.03%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $23 → $26 | $22.10 | +17.65% | 22 | Dec 12, 2025 | |
| RZLT Rezolute | Maintains: Buy | $14 → $5 | $1.80 | +177.78% | 19 | Dec 12, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $34 → $40 | $30.27 | +32.14% | 3 | Dec 9, 2025 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $340 | $268.80 | +26.49% | 30 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $30 → $11 | $11.53 | -4.60% | 16 | Dec 3, 2025 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $2.47 | +385.83% | 18 | Dec 2, 2025 | |
| PCRX Pacira BioSciences | Assumes: Buy | $38 | $26.29 | +44.54% | 3 | Nov 17, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $15 → $20 | $18.17 | +10.07% | 16 | Nov 11, 2025 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $5 → $4 | $3.88 | +3.09% | 15 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $57 → $45 | $25.23 | +78.36% | 27 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $774 → $915 | $877.94 | +4.22% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.36 | +577.97% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $95.35 | -16.10% | 35 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1 | $1.98 | -49.49% | 18 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $28.50 | +61.40% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $26.42 | +32.48% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.01 | +132.56% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $20 | $7.04 | +184.09% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $91.85 | +28.47% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $50.49 | +60.43% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $44.06 | +20.29% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.35 | +418.52% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $32.31 | +5.23% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $29.02 | -34.53% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.09 | +761.24% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.82 | +43,690.29% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.75 | +471.43% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $186.58 | -2.45% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.67 | +144.46% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $40.15 | -55.17% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $29.79 | -73.15% | 7 | Jun 11, 2019 |
Roivant Sciences
Dec 12, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $22.10
Upside: +17.65%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $1.80
Upside: +177.78%
Rapport Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $30.27
Upside: +32.14%
Praxis Precision Medicines
Dec 8, 2025
Reiterates: Buy
Price Target: $340
Current: $268.80
Upside: +26.49%
Biohaven
Dec 3, 2025
Downgrades: Neutral
Price Target: $30 → $11
Current: $11.53
Upside: -4.60%
Daré Bioscience
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $2.47
Upside: +385.83%
Pacira BioSciences
Nov 17, 2025
Assumes: Buy
Price Target: $38
Current: $26.29
Upside: +44.54%
Theravance Biopharma
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $18.17
Upside: +10.07%
Minerva Neurosciences
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $3.88
Upside: +3.09%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $25.23
Upside: +78.36%
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $877.94
Upside: +4.22%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.36
Upside: +577.97%
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $95.35
Upside: -16.10%
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $1.98
Upside: -49.49%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $28.50
Upside: +61.40%
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $26.42
Upside: +32.48%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.01
Upside: +132.56%
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $7.04
Upside: +184.09%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $91.85
Upside: +28.47%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $50.49
Upside: +60.43%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $44.06
Upside: +20.29%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.35
Upside: +418.52%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $32.31
Upside: +5.23%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $29.02
Upside: -34.53%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.09
Upside: +761.24%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.82
Upside: +43,690.29%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.75
Upside: +471.43%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $186.58
Upside: -2.45%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.67
Upside: +144.46%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $40.15
Upside: -55.17%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $29.79
Upside: -73.15%